Literature DB >> 31074413

Case Report: Trypanosoma brucei Gambiense Human African Trypanosomiasis as the Cause of Fever in an Inpatient with Multiple Myeloma and HIV-1 Coinfection.

Carl Boodman1,2, Michael Libman3,1, Momar Ndao4,1, Cedric P Yansouni3,1.   

Abstract

We report the case of a 64-year-old woman found to have urban-acquired Trypanosoma brucei (T.b.) gambiense human African trypanosomiasis (HAT) as the cause of sustained fever starting 9 months after returning to Canada from Democratic Republic of the Congo, in the context of concomitant multiple myeloma and HIV-1 coinfection. Approaches for the management of both clinical stages of T.b. gambiense HAT are well defined for endemic settings using current diagnostics and treatments. However, few data inform the diagnosis and management of patients with bone marrow suppression from active malignancy, recent anticancer therapy, or HIV coinfection. We discuss the implications of immunosuppression for diagnosis and management of T.b. gambiense HAT.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31074413      PMCID: PMC6609208          DOI: 10.4269/ajtmh.18-0889

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  28 in total

1.  Anti-sleeping sickness drugs and cancer chemotherapy.

Authors:  S V Barrett; M P Barrett
Journal:  Parasitol Today       Date:  2000-01

2.  Human African trypanosomiasis.

Authors:  Reto Brun; Johannes Blum; Francois Chappuis; Christian Burri
Journal:  Lancet       Date:  2009-10-14       Impact factor: 79.321

3.  Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa.

Authors:  Philippe Truc; Veerle Lejon; Eddy Magnus; Vincent Jamonneau; Auguste Nangouma; Didier Verloo; Laurent Penchenier; Philippe Büscher
Journal:  Bull World Health Organ       Date:  2002       Impact factor: 9.408

Review 4.  Options for field diagnosis of human african trypanosomiasis.

Authors:  François Chappuis; Louis Loutan; Pere Simarro; Veerle Lejon; Philippe Büscher
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

5.  Simultaneous occurrence of acute myocarditis and reactivated Chagas' disease in a patient with AIDS.

Authors:  A M Sartori; M H Lopes; B Caramelli; M I Duarte; P L Pinto; V Neto; M Amato Shikanai-Yasuda
Journal:  Clin Infect Dis       Date:  1995-11       Impact factor: 9.079

6.  Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007.

Authors:  Ezequiel Cordova; Analia Boschi; Juan Ambrosioni; Carolina Cudos; Marcelo Corti
Journal:  Int J Infect Dis       Date:  2008-03-11       Impact factor: 3.623

7.  Human African trypanosomiasis amongst urban residents in Kinshasa: a case-control study.

Authors:  J Robays; A Ebeja Kadima; P Lutumba; C Miaka mia Bilenge; V Kande Betu Ku Mesu; R De Deken; J Makabuza; M Deguerry; P Van der Stuyft; M Boelaert
Journal:  Trop Med Int Health       Date:  2004-08       Impact factor: 2.622

8.  Urban transmission of human African trypanosomiasis, Gabon.

Authors:  Fabrice Simon; Marie Mura; Frédéric Pagès; Gabriel Morand; Philippe Truc; Francis Louis; Philippe Gautret
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

9.  Monitoring the elimination of human African trypanosomiasis: Update to 2016.

Authors:  José R Franco; Giuliano Cecchi; Gerardo Priotto; Massimo Paone; Abdoulaye Diarra; Lise Grout; Pere P Simarro; Weining Zhao; Daniel Argaw
Journal:  PLoS Negl Trop Dis       Date:  2018-12-06

10.  GeoSentinel surveillance of illness in returned travelers, 2007-2011.

Authors:  Karin Leder; Joseph Torresi; Michael D Libman; Jakob P Cramer; Francesco Castelli; Patricia Schlagenhauf; Annelies Wilder-Smith; Mary E Wilson; Jay S Keystone; Eli Schwartz; Elizabeth D Barnett; Frank von Sonnenburg; John S Brownstein; Allen C Cheng; Mark J Sotir; Douglas H Esposito; David O Freedman
Journal:  Ann Intern Med       Date:  2013-03-19       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.